Skip to main content
SpringerLink
Log in

A Medicines Regulatory Perspective on Women’s Medicines

  • Chapter
  • First Online:
Medicines For Women

  • 1157 Accesses

Abstract

This chapter aims to give a regulator’s perspective on the issues concerning women’s medicines which have most shaped and influenced regulation – in particular in the UK and Europe. The chapter covers the history of regulation, including the role of women’s medicines; how regulation works today, in particular safety monitoring; special regulatory challenges for women’s medicines; and future regulatory prospects.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Amirthalingam et al (2014) Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet, Early Online Publication, 16 Jul 2014. doi:10.1016/S0140-6736(14)60686-3Cite or Link using doi:http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60686-3/abstract

  • Armitage M, Nooney JM (2004) Advice from the Committee on Safety of Medicines on hormone replacement therapy. In: Critchley H, Gebbi A, Beral V (eds) Menopause and hormone replacement. RCOG Press, London, pp 325–335

    Google Scholar 

  • Avery AJ et al (2011) Evaluation of patients reporting of adverse drug reactions to the UK ‘Yellow Card Scheme’: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. MHRA HTA programme. www.hta.ac.uk

  • Beral V et al (2003) Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427. Erratum in: Lancet 362:1160

    Google Scholar 

  • Blackburn SCF, Raine JM (2014) The principles behind risk management in the European Union. In: Andrews EB, Moore N (eds) Mann’s pharmacovigilance, 3rd edn. Wiley Blackwell, New York, pp 153–169

    Chapter  Google Scholar 

  • Branch SK, Agranat I (2014) “New Drug” designations for new therapeutic entities: new active substance, new chemical entity, new biological entity, new molecular entity. J Med Chem. doi:10.1021/jm402001w

  • Clark DW, Harrison-Woolrych M (2006) The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions. Curr Drug Saf 1(2):169–178

    Article  PubMed  Google Scholar 

  • Dolk H (2005) EUROCAT: 25 years of European Surveillance of congenital anomalies. Arch Dis Child Fetal Neonatal Ed 90:F355–F358. doi:10.1136/adc.2004.062810

  • Donegan K et al (2013) Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK. Vaccine 31:4961–4967

    Article  CAS  PubMed  Google Scholar 

  • Donegan K et al (2014) Safety of Pertussis vaccination in pregnant women in UK: observational study. BMJ 349. http://dx.doi.org/10.1136/bmj.g4219 (published 11 Jul 2014)

  • Duijnhoven RG et al (2013) Number of patients studied prior to approval of new medicines: a database analysis. PLOS Med 10(3):e1001407

    Article  PubMed Central  PubMed  Google Scholar 

  • Edmonds SE, Montgomery JC (2003) Reversible ovarian failure induced by a Chinese herbal medicine: lei gong teng. BJOG 110:77–78

    Google Scholar 

  • European Medicines Agency (1997) Guideline on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women. EMEA/CHMP/021/97 Rev. 1. http://www.ema.europa.eu.ema/index.jsp?curl=pages/regulation/general/general_content_000399.jsp&mid=WC0b01ac0580034cf1

  • European Medicines Agency (2006) Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. CPMP/EWP/552/95 Rev. 2. http://www.ema.uropa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000409.jsp&mid=WC0b01ac0580034cf1. Accessed 22 Aug 2014

  • European Medicines Agency (2007) European Medicines Agency recommends withdrawal of national products containing Veralipride. EMEA/299873/2007

    Google Scholar 

  • European Medicines Agency (2012) Alli (orlistat) EPAR summary for the public EMA/307667/2012. EMEA/H/C/000854

    Google Scholar 

  • European Medicines Agency (2013a) Assessment report for short acting beta agonists (SABAs) containing medicinal products authorised in obstetric indications. EMA/664276/2013

    Google Scholar 

  • European Medicines Agency (2013b) PSUR assessment report for Protelos/Osseor. EMA/PRAC/136656/2013

    Google Scholar 

  • European Medicines Agency (2014a) PRAC recommends restricted use of bromocriptine for stopping breast milk production. EMA/409529/2014

    Google Scholar 

  • European Medicines Agency (2014b) Assessment report for combined hormonal contraceptives containing medicinal products. EMA/739865/2013

    Google Scholar 

  • European Medicines Agency (2014c) Herceptin (trustuzumab) EPAR summary for the public. EMA/981900/2011, EMA/H/C/000278

    Google Scholar 

  • European Medicines Agency (2014d) Guideline on key aspects for the use of pharmacogenomics methodologies in the pharmacovigilance evaluation of medicinal products (Draft). EMA/281371/2013

    Google Scholar 

  • FDA (2004) Guidance for industry pharmacokinetics in pregnancy – study design, data analysis, and impact on dosing and labelling. http://www.fda.gov/ScienceResearch/SpecialTopics/WomensHealthResearch/ucm133348.htm#_Toc82327337. Accessed 22 Aug 2014

  • Foy M, Barrow P, Raine JM (2014) Spontaneous reporting: United Kingdom. In: Andrews EB, Moore N (eds) Mann’s pharmacovigilance, 3rd edn. Wiley Blackwell, New York, pp 185–201

    Chapter  Google Scholar 

  • Grossman G (2008) Should the contraceptive pill be available without prescription? Yes. BMJ 337:a3044

    Article  PubMed  Google Scholar 

  • Haghikia A et al (2013) Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol 108:366

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Halkein J et al (2013) Micro RNA –146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Investig 123(5):2143–2154

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Harrison-Woolrych M (2014) Prescription event monitoring in New Zealand. In: Andrews EB, Moore N (eds) Mann’s pharmacovigilance, 3rd edn. Wiley Blackwell, New York, pp 385–402

    Chapter  Google Scholar 

  • Hazell L et al (2013) How do patients contribute to signal detection? A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK’s Yellow Card Scheme. Drug Saf. doi:10.1007/S40264-013-0021-2

  • Henderson L et al (2002) St John’s Wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 54(4):349–356

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • ICH (1996) Guideline for good clinical practice E6(R1). http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html. Accessed 22 Aug 2014

  • ICH (2010) Guideline on non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3(R2). http://www.ich.org/products/guidelines/multidisciplinary/article/multidisciplinary-guidelines.html. Accessed 22 Aug 2014

  • Jacobs AC, Hatfield KP (2012) History of chronic toxicity and animal carcinogenicity studies for pharmaceuticals. Vet Pathol 50(2):324–333

    Article  PubMed  Google Scholar 

  • Kieler H et al (2012) Selective serotonin reuptake inhibitors and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 344:d8012. doi:10.11.36/bmj.d8012

    Google Scholar 

  • Kim JH, Scialli AR (2011) Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci 122(1):1–6

    Google Scholar 

  • Koren G et al (2006) Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 368(9536):704

    Article  PubMed  Google Scholar 

  • Layton D et al (2011) Modified prescription-event monitoring studies: a tool for pharmocovigilance and risk management. Drug Saf 34(12):e1–e9

    Article  PubMed  Google Scholar 

  • Lord GM et al (1999) Nephropathy caused by Chinese herbs in UK. Lancet 354(9177):481–482

    Article  CAS  PubMed  Google Scholar 

  • Mallal S et al (2008) 2008 HLA-B* 5701 screening for hypersensitivity to abacavir. N Engl J Med 358:568–579

    Article  PubMed  Google Scholar 

  • Marston C et al (2005) Impact on contraceptive practice of making emergency oral contraception available over the counter in Great Britain. BMJ 331:271

    Article  PubMed Central  PubMed  Google Scholar 

  • McBride WG (1961) Thalidomide and congenital abnormalities. Letter to the Editor. Lancet 278(7216):1358

    Article  Google Scholar 

  • MHRA (2007a) UK public assessment report hormone replacement therapy: safety update. http://www.mhra.gov.uk/home/groups/pl-p-documents/websiteresources/con2032228.pdf

  • MHRA (2007b) Hormone replacement therapy: updated advice. Drug Saf Update 1(2) September 2007

    Google Scholar 

  • MHRA (2009a) Ipsos Mori report shows that 77 % adults agree that it is important that herbal medicines are regulated. http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON036071

  • MHRA (2009b) Unlicensed eczema creams found to contain steroids, March 2009. www.mhra.gov.uk

  • MHRA (2011) Yellow Cards which made a difference. Drug Saf Update 5(4), November 2011

    Google Scholar 

  • MHRA (2012) MHRA Public Assessment Report Cervarix HPV vaccine: update on UK safety experience at end of 4 years use in the HPV routine. http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con213228.pdf

  • MHRA (2013) Review of the shortcomings of product information for medicines – UK Government view www.mhra.gov.uk

  • MHRA (2014a) Guidance on reporting suspected adverse drug reactions in infants and children following maternal administration in pregnancy (in press)

    Google Scholar 

  • MHRA (2014b) St John’s Wort: interaction with hormonal contraceptives, including implants – reduced contraceptive effect. Drug Saf Update 7(8), March 2014

    Google Scholar 

  • Mt-Isa S et al, on behalf of the IMI-PROTECT Benefit Risk participants (2014) Balancing benefit and risk of medicines: a systematic review and classification of available methodologies. Pharmacoepidemiol Drug Saf. doi:10.1002/pds.3636

  • Plening S et al (2012) Impact of safety-related regulatory action on clinical practice – a systematic review. Drug Saf 35(5):373–385

    Article  Google Scholar 

  • Raine June M (2014) Off-label use of medicines: legal aspects. In: Thomsen HS, Webb JAW (eds) Contrast media. Springer, Berlin

    Google Scholar 

  • Rawlins M (2008) De testimonio. On the evidence for decisions about the use of therapeutic interventions. Lancet 372:2152–2161

    Article  PubMed  Google Scholar 

  • Raymond E et al (2007) Population effect of increased access to emergency contraceptive pills: a systematic review. Obstet Gynaecol 109(1):181–188

    Article  Google Scholar 

  • Raynor DK (2013) User testing in developing patient medication information in Europe. Res Soc Adm Pharm 9(5):640–645

    Article  CAS  Google Scholar 

  • Raynor DK et al (2007) A systematic review of quantitative and qualitative research on the role and effectiveness of written information available to patients about individual medicines. Health Technol Assess 11:5. www.hta.ac.uk

  • Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al (2002) Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333

    Article  CAS  PubMed  Google Scholar 

  • Waller PC, Evans SJ (2003) A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 12:17–29

    Article  PubMed  Google Scholar 

  • WHO (2014) Thalidomide embryopathy – report of a meeting of experts, Geneva, 24–25 Feb 2014 (draft)

    Google Scholar 

Download references

Acknowledgements

Our thanks go to Akosua Adjei, Linda Anderson, Paul Barrow, Rob Higgins, Tahira Jan, Beryl Keeley and Jan MacDonald for helpful comments and suggestions.

Author information

Authors and Affiliations

  1. Medicines and Healthcare products Regulatory Agency, 151 Buckingham Palace Road, Victoria, SW1W 9SZ, London, UK

    June M. Raine & Janet M. Nooney

Authors
  1. June M. Raine
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Janet M. Nooney
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to June M. Raine .

Editor information

Editors and Affiliations

  1. Dean’s Department, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

    Mira Harrison-Woolrych

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Raine, J.M., Nooney, J.M. (2015). A Medicines Regulatory Perspective on Women’s Medicines. In: Harrison-Woolrych, M. (eds) Medicines For Women. Adis, Cham. https://doi.org/10.1007/978-3-319-12406-3_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-12406-3_15

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-12405-6

  • Online ISBN: 978-3-319-12406-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation